vs

Side-by-side financial comparison of LandBridge Co LLC (LB) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $56.8M, roughly 1.5× LandBridge Co LLC). LandBridge Co LLC runs the higher net margin — 14.2% vs -38.1%, a 52.2% gap on every dollar of revenue. On growth, LandBridge Co LLC posted the faster year-over-year revenue change (55.6% vs 20.2%). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs 24.8%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

LB vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.5× larger
PRCT
$83.1M
$56.8M
LB
Growing faster (revenue YoY)
LB
LB
+35.4% gap
LB
55.6%
20.2%
PRCT
Higher net margin
LB
LB
52.2% more per $
LB
14.2%
-38.1%
PRCT
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
72.8%
24.8%
PRCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
LB
LB
PRCT
PRCT
Revenue
$56.8M
$83.1M
Net Profit
$8.1M
$-31.6M
Gross Margin
64.9%
Operating Margin
60.0%
-4.1%
Net Margin
14.2%
-38.1%
Revenue YoY
55.6%
20.2%
Net Profit YoY
-83.7%
-27.9%
EPS (diluted)
$0.24
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LB
LB
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$56.8M
$76.4M
Q3 25
$50.8M
$83.3M
Q2 25
$47.5M
$79.2M
Q1 25
$44.0M
$69.2M
Q4 24
$36.5M
$68.2M
Q3 24
$28.5M
$58.4M
Q2 24
$26.0M
$53.4M
Net Profit
LB
LB
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$8.1M
$-29.8M
Q3 25
$8.1M
$-21.4M
Q2 25
$7.5M
$-19.6M
Q1 25
$6.5M
$-24.7M
Q4 24
$49.3M
$-18.9M
Q3 24
$2.7M
$-21.0M
Q2 24
$-57.7M
$-25.6M
Gross Margin
LB
LB
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
LB
LB
PRCT
PRCT
Q1 26
-4.1%
Q4 25
60.0%
-40.6%
Q3 25
60.8%
-27.8%
Q2 25
60.0%
-28.0%
Q1 25
57.0%
-39.7%
Q4 24
49.4%
-28.9%
Q3 24
11.2%
-38.4%
Q2 24
-197.4%
-50.3%
Net Margin
LB
LB
PRCT
PRCT
Q1 26
-38.1%
Q4 25
14.2%
-39.1%
Q3 25
15.9%
-25.7%
Q2 25
15.8%
-24.7%
Q1 25
14.7%
-35.8%
Q4 24
135.2%
-27.6%
Q3 24
9.3%
-35.9%
Q2 24
-222.1%
-48.0%
EPS (diluted)
LB
LB
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.24
$-0.54
Q3 25
$0.26
$-0.38
Q2 25
$0.24
$-0.35
Q1 25
$0.20
$-0.45
Q4 24
$-0.34
Q3 24
$-0.04
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LB
LB
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$30.7M
$245.6M
Total DebtLower is stronger
$570.7M
$51.7M
Stockholders' EquityBook value
$340.3M
$347.7M
Total Assets
$1.4B
$487.1M
Debt / EquityLower = less leverage
1.68×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LB
LB
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$30.7M
$286.5M
Q3 25
$28.3M
$294.3M
Q2 25
$20.3M
$302.7M
Q1 25
$14.9M
$316.2M
Q4 24
$37.0M
$333.7M
Q3 24
$14.4M
$196.8M
Q2 24
$24.6M
$214.1M
Total Debt
LB
LB
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$570.7M
$51.6M
Q3 25
$366.1M
$51.6M
Q2 25
$370.9M
$51.5M
Q1 25
$375.5M
$51.5M
Q4 24
$385.5M
$51.5M
Q3 24
$242.4M
$51.4M
Q2 24
$360.8M
$51.4M
Stockholders' Equity
LB
LB
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$340.3M
$365.9M
Q3 25
$272.0M
$380.3M
Q2 25
$266.4M
$385.8M
Q1 25
$217.0M
$389.2M
Q4 24
$211.8M
$402.2M
Q3 24
$97.2M
$241.2M
Q2 24
$296.4M
$251.8M
Total Assets
LB
LB
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$1.4B
$508.1M
Q3 25
$1.1B
$511.5M
Q2 25
$1.1B
$513.1M
Q1 25
$1.0B
$519.4M
Q4 24
$1.0B
$534.0M
Q3 24
$689.9M
$374.1M
Q2 24
$710.5M
$374.4M
Debt / Equity
LB
LB
PRCT
PRCT
Q1 26
0.15×
Q4 25
1.68×
0.14×
Q3 25
1.35×
0.14×
Q2 25
1.39×
0.13×
Q1 25
1.73×
0.13×
Q4 24
1.82×
0.13×
Q3 24
2.49×
0.21×
Q2 24
1.22×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LB
LB
PRCT
PRCT
Operating Cash FlowLast quarter
$126.3M
Free Cash FlowOCF − Capex
$122.0M
FCF MarginFCF / Revenue
214.9%
Capex IntensityCapex / Revenue
7.5%
Cash ConversionOCF / Net Profit
15.68×
TTM Free Cash FlowTrailing 4 quarters
$207.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LB
LB
PRCT
PRCT
Q1 26
Q4 25
$126.3M
$-10.3M
Q3 25
$34.9M
$-6.6M
Q2 25
$37.3M
$-15.0M
Q1 25
$15.9M
$-17.0M
Q4 24
$67.6M
$-32.4M
Q3 24
$7.5M
$-18.8M
Q2 24
$16.0M
$-15.7M
Free Cash Flow
LB
LB
PRCT
PRCT
Q1 26
Q4 25
$122.0M
$-12.2M
Q3 25
$33.7M
$-9.5M
Q2 25
$36.1M
$-17.8M
Q1 25
$15.8M
$-18.8M
Q4 24
$66.7M
$-33.6M
Q3 24
$7.1M
$-19.0M
Q2 24
$15.7M
$-16.8M
FCF Margin
LB
LB
PRCT
PRCT
Q1 26
Q4 25
214.9%
-15.9%
Q3 25
66.3%
-11.4%
Q2 25
75.9%
-22.5%
Q1 25
36.0%
-27.2%
Q4 24
182.6%
-49.2%
Q3 24
25.1%
-32.6%
Q2 24
60.4%
-31.4%
Capex Intensity
LB
LB
PRCT
PRCT
Q1 26
Q4 25
7.5%
2.4%
Q3 25
2.3%
3.4%
Q2 25
2.6%
3.5%
Q1 25
0.2%
2.7%
Q4 24
2.7%
1.7%
Q3 24
1.1%
0.4%
Q2 24
1.4%
2.0%
Cash Conversion
LB
LB
PRCT
PRCT
Q1 26
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
Q1 25
2.46×
Q4 24
1.37×
Q3 24
2.80×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LB
LB

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons